LOTEMAX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LOTEMAX (LOTEMAX).
Lotemax (loteprednol etabonate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2 activity, thereby reducing arachidonic acid release and subsequent synthesis of prostaglandins and leukotrienes.
| Metabolism | Primarily hydrolyzed by esterases in ocular tissues to an inactive metabolite; systemic absorption minimal with hepatic metabolism via CYP450 enzymes (minor). |
| Excretion | Approximately 80% of the dose is excreted in the feces via biliary elimination as parent drug and metabolites, and about 20% is excreted in the urine as metabolites. |
| Half-life | The terminal elimination half-life is approximately 1.5–3 hours. Due to rapid clearance, systemic accumulation is minimal with topical ocular administration. |
| Protein binding | Loteprednol etabonate is approximately 80% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | The volume of distribution is approximately 0.5–1 L/kg, suggesting distribution into total body water. Due to high lipophilicity, it partitions into ocular tissues. |
| Bioavailability | Systemic bioavailability after topical ocular administration is very low (<1%) due to extensive first-pass metabolism and poor absorption across the cornea. Oral bioavailability has not been characterized as it is not administered orally. |
| Onset of Action | Clinical effect (reduction of ocular inflammation) typically begins within 2–4 hours after topical ocular instillation. |
| Duration of Action | Duration of action is approximately 6–8 hours after a single dose, corresponding to the dosing interval of every 4–6 hours for acute conditions. |
| Molecular Weight | 420.95 |
One drop of 0.5% ophthalmic suspension into the affected eye(s) four times daily for up to 2 weeks.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific dose adjustment recommended; use with caution in severe hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; no specific weight-based guidelines available. |
| Geriatric use | No specific dose adjustment required; use same as adult dosing. |
| 1st trimester | Corticosteroids have been associated with increased risk of cleft palate in animal studies. Use only if potential benefit justifies risk. |
| 2nd trimester | Corticosteroids may cause fetal growth restriction and adrenal suppression. Limited human data; avoid prolonged use. |
| 3rd trimester | Avoid use near term due to potential neonatal adrenal suppression. |
Clinical note
Comprehensive clinical and safety monograph for LOTEMAX (LOTEMAX).
| Placental transfer | Systemic corticosteroids cross placenta; ophthalmic administration has minimal systemic absorption, so transfer is expected to be negligible. |
| Breastfeeding | Systemic absorption of ophthalmic loteprednol is minimal, but prolonged or high-dose use may expose infant. Consider benefit of treating maternal condition. |
■ FDA Black Box Warning
Not applicable.
| Serious Effects |
Hypersensitivity to loteprednol or any componentViral diseases of cornea (e.g., herpes simplex)Fungal infections of ocular structuresUntreated bacterial eye infectionsGlaucoma (relative)
| Precautions | Prolonged use may lead to elevated intraocular pressure (IOP); monitor IOP., May increase risk of secondary ocular infections; caution in herpetic infections., Cataract formation with long-term use., Delayed wound healing., May cause thinning of cornea and sclera. |
| Food/Dietary | No specific food interactions. Avoid alcohol if it exacerbates ocular irritation or inflammation. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | Category C: No adequate studies in pregnant women. In animal studies, topical ocular corticosteroids caused teratogenicity at maternally toxic doses, including cleft palate, umbilical hernia, and delayed ossification. Risk cannot be ruled out; use only if potential benefit justifies risk. First trimester: avoid if possible. Second/third trimester: limited data, but systemic absorption is low with ocular administration. |
| Fetal Monitoring | Monitor intraocular pressure (IOP) during prolonged use; pregnancy may alter IOP. Check for cataract formation or secondary infections. Assess fetal growth and development if used chronically in pregnancy. |
| Fertility Effects | No specific human data; animal studies show no impairment of fertility at clinically relevant doses. Corticosteroids may affect hormonal balance theoretically, but no evidence of significant impact with ocular use. |
| Lotemax (loteprednol etabonate 0.5%) is a site-specific corticosteroid that undergoes rapid ester hydrolysis to an inactive metabolite, reducing systemic toxicity. It is first-line for mild-to-moderate postoperative inflammation and seasonal allergic conjunctivitis. Avoid in epithelial herpes simplex keratitis (dendritic ulcers). Shake suspension well before use. Monitor for elevated intraocular pressure (IOP), especially in patients with glaucoma; IOP elevation is less than with prednisolone acetate. |
| Patient Advice | Shake the bottle vigorously before each use to ensure uniform suspension. · Apply the prescribed number of drops into the affected eye(s) and avoid touching the dropper tip to the eye or any surface. · Wait at least 5 minutes between applying different eye medications to prevent washout. · Do not wear contact lenses during treatment for eye inflammation; only reinsert if recommended by your doctor. · Report any eye pain, vision changes, redness, or discharge immediately. · If you have glaucoma or a history of elevated eye pressure, monitor closely as steroids can raise IOP. · Do not stop using this medication abruptly; taper as directed to avoid inflammation rebound. · If you miss a dose, apply it as soon as possible unless it is almost time for the next dose; do not double the dose. |